Skip to main content
Premium Trial:

Request an Annual Quote

Biocept: Samuel Riccitelli

Biocept has appointed Samuel Riccitelli to its board of directors, effective immediately, and ahead of the planned retirement of Bruce Huebner, who will leave the board on Nov. 30, 2020Riccitelli boasts 35 years of experience in the molecular diagnostics industry, having served in executive-level positions and on the boards of multiple publicly traded companies. At Biocept, he will initially serve on the audit committee and the science and technology committee.

Riccitelli currently serves as an independent consultant to healthcare companies and is a director of OrthoPediatrics, a company focused on the orthopedic implant needs of children. Prior to that he was CEO of Pathnostics, a molecular diagnostics company focused on improving antibiotic stewardship. He also served as chairman of Precipio; president, CEO, and director of Signal Genetics; and executive VP and chief operating officer of Genoptix. Riccitelli received a BA from Washington and Jefferson College and an MS in engineering from The University of Texas.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.